Annandale, NJ 08801
ph: 908.849.4854
info
Orphan Therapeutics, LLC is a privately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for its first product terlipressin for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US, Canada and Japan. In March 2010, Orphan Therapeutics licensed the New Drug Application (NDA) and its development rights for terlipressin in North America and Australia to Ikaria Inc., which was acquired by Mallinckrodt in April 2015. Orphan Therapeutics has a continued commitment to assist the Mallinckrodt team through the FDA approval process.
November 11, 2019
Mallinckrodt Presents Positive Results from its CONFIRM Study
October 21, 2019
Mallinckrodt to Present Results from its Pivotal Phase 3 CONFIRM Study
August 15, 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial
December 7, 2015
Mallinckrodt plc Discusses R&D Initiatives, Company Outlook at Investor Briefing
Copyright 2019 - Orphan Therapeutics. All rights reserved.
Annandale, NJ 08801
ph: 908.849.4854
info